This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Prognostic Value of Prothrombin Fragments 1+2 for Pulmonary Embolism Incidence

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2010 by Hillel Yaffe Medical Center.
Recruitment status was:  Not yet recruiting
Information provided by:
Hillel Yaffe Medical Center Identifier:
First received: March 1, 2010
Last updated: NA
Last verified: March 2010
History: No changes posted
To determine the possible association of prothrombin fragments 1+2 elevation with incidents of pulmonary embolism in patients with COPD exacerbation.

Condition Intervention
Pulmonary Disease, Chronic Obstructive Disease Exacerbation Pulmonary Embolism Prothrombin Fragments Other: CT pulmonary angio, blood tests

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:

Further study details as provided by Hillel Yaffe Medical Center:

Groups/Cohorts Assigned Interventions
COPD exacerbation
Patients admitted to hospital with COPD exacerbation
Other: CT pulmonary angio, blood tests


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients admitted to hospital due to COPD exacerbation

Inclusion Criteria:

  • COPD exacerbation
  • Able to give informed consent
  • Able to perform spirometry

Exclusion Criteria:

  • Known malignancy
  • Known hypercoagulable state
  • Receiving anticoagulant treatment
  • Pregnancy
  • Renal failure
  • Allergy to Iodine
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01078792

Hillel Yaffe Medical Center Not yet recruiting
Hadera, Israel, 38100
Contact: M Beckerman, MD   
Principal Investigator: M Beckerman, MD         
Sponsors and Collaborators
Hillel Yaffe Medical Center
  More Information

Responsible Party: Marinella Beckerman, Hillel Yaffe Medical Center Identifier: NCT01078792     History of Changes
Other Study ID Numbers: 0001-10
Study First Received: March 1, 2010
Last Updated: March 1, 2010

Additional relevant MeSH terms:
Lung Diseases
Pulmonary Embolism
Chronic Disease
Pulmonary Disease, Chronic Obstructive
Disease Progression
Respiratory Tract Diseases
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Disease Attributes
Pathologic Processes
Lung Diseases, Obstructive processed this record on June 22, 2017